Role of CXCR3 signaling in response to anti-PD-1 therapy.

ABSTRACT:

Background

Tumor mutations and tumor microenvironment are associated with resistance to cancer immunotherapies. However, peripheral T cell in effective anti-programmed death 1 (PD-1) antibody treatment is poorly understood.

Methods

Mass spectrometry and conventional flow cytometry were used to investigate peripheral blood cells isolated from patients. Furthermore, melanoma mouse model was performed to assess the role of CXCR3 signaling in anti-PD-1 antibody treatment.

Findings

We revealed a marked increase in the percentage of CXCR3⁺ T cells in the blood of cancer patients after the first pembrolizumab infusion. This percentage decreased after the second infusion in responsive patients, whereas a sustained high percentage of CXCR3⁺ T cells was ob

SUBMITTER: Han X 

PROVIDER: S-EPMC6838359 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature